Long-term Outcomes and Biomarker Correlates of a Multi-institutional Phase II Study of Hypofractionated Proton Beam Therapy for Unresectable Primary Liver Tumors
Year: 2026
Type: article
Study design: Clinical Trial
Source: Clinical Cancer Research
Authors: Hannah J. Roberts, Theodore S. Hong, Zoe Guan, Beow Y. Yeap, Edgar Ben-Josef, Andrew X. Zhu, Lipika Goyal, Joseph W. Franses, David P. Ryan, Jill N. Allen, Jeffrey W. Clark, Leilana Ly, Lorraine C. Drapek, Kenneth Tanabe, Cristina R. Ferrone, Eugene J. Koay, Christopher H. Crane, Thomas F. DeLaney, Dan G. Duda, Jennifer Y. Wo
Institutions: Harvard University, Massachusetts General Hospital, Dana-Farber Cancer Institute, University of Pennsylvania, Stanford Medicine, Stanford University, University of Chicago, Cedars-Sinai Medical Center, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Dartmouth–Hitchcock Medical Center
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Keywords: proton therapy, hypofractionated radiotherapy, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, unresectable liver tumors, plasma biomarkers, disease progression, hypoxia, vascular remodeling, inflammation, stromal activation, liver regeneration, overall survival, progression-free survival, local control
Open Access status: closed
Awards: PROTON RADIATION THERAPY RESEARCH, Defining Optimal Radiotherapy Dose and Fractionation in Combination with Preoperative Immuno-Chemotherapy in Early-Stage Triple Negative Breast Cancer, A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients, Dana-Farber/Harvard Cancer Center, G9001397337
OpenAlex ID: W7223146428
